Abstract Objective To study the effects of recombinant human interleukin-11 (rhIL-11) on the proliferation and apoptosis of rat intestinal epithelial cell line (IEC-6). Methods IEC-6 cells were treated with LPS to establish necrotizing enterocolitis (NEC) model in vitro. rhIL-11 (100 ng/mL) was administered following LPS treatment and these cells were used as the IL-11 treatment group. The cells treated with normal saline only served as the control group. MTT assay was used to determine an optimal concentration (5-200 μg/mL) and time (1-24 h). MTT assay was used to measure the proliferation of IEC-6 cells at 3, 6, 9 and 12 hours after rhIL-11 treatment. Flow cytometry was used to evaluate the apoptosis of IEC-6 cells. Results IEC-6 cells treated with various concentrations of LPS at various time points showed a lower proliferation than the control group (PPPPConclusions rhIL-11 can promote proliferation and reduce apoptotic and necrotic rates of IEC-6 cells treated with LPS.
CAI Na,FENG Zhi-Chun,WANG Rui-Juan. Effects of recombinant human interleukin-11 on LPS-induced intestinal epithelial cell injury in rats[J]. CJCP, 2014, 16(5): 529-533.
CAI Na,FENG Zhi-Chun,WANG Rui-Juan. Effects of recombinant human interleukin-11 on LPS-induced intestinal epithelial cell injury in rats[J]. CJCP, 2014, 16(5): 529-533.
Yee WH, Soraisham AS, Shah VS, et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants[J]. Pediatrics, 2012, 129(2): 298-304.
Kuenzler KA, Pearson PY, Schwartz MZ. IL-11 pretreatment reduces cell death after intestinal ischemia-reperfusion[J]. J Surg Res, 2002, 108(2): 268-272.
[4]
Du X, Liu Q, Yang Z, et al. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis[J]. Am J Physiol, 1997, 272(3Pt 1): 545-552.
[5]
Fiore NF, Ledniczky G, Liu Q, et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection[J]. J Pediatr Surg, 1998, 33(1): 24-29.
[6]
Dickinson EC, Tuncer R, Nadler EP, et al. Recombinant human interleukin-11 prevents mucosal atrophy and bowel shortening in the defunctionalized intestine[J]. J Pediatr Surg, 2000, 35(7): 1079-1083.
[7]
Peterson RL, Wang L, Albert L, et al. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease[J]. Lab Invest, 1998, 78(12): 1503-1512.
[8]
McElroy SJ, Hobbs S, Kallen M, et al. Transactivation of EGFR by LPS Induces COX-2 Expression in Enterocytes[J]. PLoS One, 2012, 7(5): 38373.
Schwertschlag US, Trepicchio WL, Dykstra KH, et al. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11[J]. Leukemia, 1999, 13(9): 1307-1315.
[12]
Greenwood-Van Meerveld B, Tyler K, Keith JC Jr. Recombinant human interleukin-11 modulates ion transport and mucosal inflammation in the small intestine and colon[J]. Lab Invest, 2000, 80(8): 1269-1280.
[13]
Nadler EP, Stanford A, Zhang XR, et al. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease[J]. J Pediatr Surg, 2001, 36(8): 1122-1129.
[14]
Kuenzler KA, Pearson PY, Schwartz MZ. IL-11 pretreatment reduces cell death after intestinal ischemia-reperfusion[J]. J Surg Res, 2002, 108(2): 268-272.
[15]
Du X, Liu Q, Yang Z, et al. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis[J]. Am J Physiol, 1997, 272(3 Pt 1): 545-552.
[16]
Dickinson EC, Tuncer R, Nadler EP, et al. Recombinant human interleukin-11 prevents mucosal atrophy and bowel shortening in the defunctionalized intestine[J]. J Pediatr Surg, 2000, 35(7): 1079-1083.
Mollen KP, Gribar SC, Anand RJ, et al. Increased expression and internalization of the endotoxin coreceptor CD14 in enterocytes occurs as an early event in the development of experimental necrotizing enterocolitis[J]. J Pediatr Surg, 2008, 43(6): 1175-1181.
[19]
Peterson RL, Wang L, Albert L, et al. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease[J]. Lab Invest, 1998, 78(12): 1503-1512.
